Trial Condition(s):

Chronic Bronchitis, Disease Exacerbation

VICTOR - Avelox® intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis (VICTOR)

Bayer Identifier:

14495

ClinicalTrials.gov Identifier:

NCT00876577

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).

Inclusion Criteria
- Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information

Trial Summary

Enrollment Goal
1206
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, China

Status
Completed
 

Trial Design